NDA 211349 · Astellas
Xospata
Gilteritinib Fumarate · Oral
NovelPriority reviewOrphanLast checked: Nov 19, 2026Latest source record: Jan 12, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2018
Nov 28, 2018
Approved uses
2
Original approval plus efficacy supplements
Registered trials
67
12 Phase 3, 28 recruiting
FAERS reports
4,079
3,848 serious, 1,051 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: DIFFERENTIATION SYNDROME Patients treated with XOSPATA have experienced symptoms of differentiation syndrome, which can be fatal or life-threatening if not treated. Symptoms may include fever, dyspnea, hypoxia, pulmonary infiltrates, pleural or pericardial effusions, rapid weight gain or peripheral edema, hypotension, or renal dysfunction. If differentiation syndrome is suspected, initiate corticosteroid therapy and hemodynamic monitoring until symptom resolution [see Warnings and Precautions ( 5.1 ) and Adverse Reactions ( 6.1 )] . WARNING: DIFFERENTIATION SYNDROME See full prescribing information for complete boxed warning. Patients treated with XOSPATA have experienced symptoms of differentiation syndrome, which can be fatal if not treated. If differentiation syndrome is suspected, initiate corticosteroid therapy and hemodynamic monitoring until symptom resolution. ( 5.1 ,...
What it is approved for
From the label in effect Oct 1, 2026.
XOSPATA is a kinase inhibitor indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test. ( 1.1 ) 1.1 Relapsed or Refractory Acute Myeloid Leukemia XOSPATA is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation as detected by an FDA-approved test.
Mechanism: Gilteritinib is a small molecule that inhibits multiple receptor tyrosine kinases, including FMS-like tyrosine kinase 3 (FLT3). Gilteritinib demonstrated the ability to inhibit FLT3 receptor signaling and proliferation in cells exogenously expressing FLT3 including FLT3-ITD, tyrosine kinase domain mutations (TKD) FLT3-D835Y and FLT3-ITD-D835Y, and it induced apoptosis in leukemic cells expressing FLT3-ITD.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 29, 2019 Supplement 1 · Efficacy · priority review LabelMedication GuideLetter
- Nov 28, 2018 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelLetterReview
1 products under this application
- XOSPATA · GILTERITINIB FUMARATE EQ 40MG BASE · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Gilteritinib" as an intervention, any sponsor and status, largest first.
- Study of Biomarker-Based Treatment of Acute Myeloid LeukemiaPivotal-lookingRecruiting
Beat AML, LLCAcademic, hospital or other
NCT03013998 · 3,000 participants (planned) · Start Nov 2016 · Primary completion Dec 2032
Drug: Samalizumab (BAML-16-001-S1); BI 836858 (BAML-16-001-S2) and 45 more · For: Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Sites: Phoenix, Arizona; Scottsdale, Arizona; Los Angeles, California · 31 sites in all
National Cancer Institute (NCI)NIH
NCT05564390 · 2,000 participants (planned) · Start Jun 18, 2024 · Primary completion May 15, 2029
Drug: Azacitidine; Azacitidine and 18 more · For: Acute Myeloid Leukemia; Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm; Acute Myeloid Leukemia Post Cytotoxic Therapy and 2 more
Sites: Birmingham, Alabama; Phoenix, Arizona; Tucson, Arizona · 360 sites in all
- A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 MutationsPivotal-lookingRecruiting
Children's Oncology GroupResearch network
NCT04293562 · 1,400 participants (planned) · Start Jul 21, 2020 · Primary completion Jun 30, 2029
Drug: Asparaginase Erwinia chrysanthemi; Cytarabine and 9 more · For: Acute Myeloid Leukemia
Sites: Birmingham, Alabama; Mobile, Alabama; Mesa, Arizona · 206 sites in all
- A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive ChemotherapyPivotal-lookingActive, not recruiting
Stichting Hemato-Oncologie voor Volwassenen NederlandAcademic, hospital or other
NCT04027309 · 777 participants · Start Dec 20, 2019 · Primary completion Oct 2025
Drug: Gilteritinib; Midostaurin · For: Acute Myeloid Leukemia; Myelodysplastic Syndrome With Excess Blasts-2
Sites: Adelaide, Australia; Brisbane, Australia; Camperdown, Australia · 193 sites in all
Sumitomo Pharma America, Inc.Industry
NCT04988555 · 606 participants (planned) · Start Feb 28, 2022 · Primary completion Jun 30, 2027
Drug: Enzomenib; azoles and 4 more · For: Leukemia, Myeloid, Acute; Leukemia, Lymphocytic, Acute; Multiple Myeloma and 1 more
Sites: Newport Beach, California; Palo Alto, California; Denver, Colorado · 104 sites in all
- MRD-guided Maintenance Post-HCT: Gilteritini vs SorafenibPivotal-lookingRecruiting
The First Affiliated Hospital of Soochow UniversityAcademic, hospital or other
NCT07463651 · 594 participants (planned) · Start May 1, 2026 · Primary completion May 31, 2028
Drug: Gilteritinib; Sorafenib · For: Acute Myeloid Leukemia (AML); FLT3-ITD Mutation; Allogeneic Hematopoietic Cell Transplantation (HCT) and 3 more
Sites: Suzhou, China; Shanghai, China
- MRD-positive AML Clinical StudyPivotal-lookingRecruiting
Institute of Hematology & Blood Diseases Hospital, ChinaAcademic, hospital or other
NCT07131059 · 537 participants (planned) · Start May 11, 2024 · Primary completion May 10, 2028
Drug: Ivosidenib; Gilteritinib and 10 more · For: AML, Adult
Sites: Tianjin, China
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT02115295 · 508 participants (planned) · Start May 19, 2014 · Primary completion May 31, 2030
Drug: Cladribine; Cytarabine and 4 more · For: Acute Biphenotypic Leukemia; Acute Myeloid Leukemia; Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive and 11 more
Sites: Houston, Texas
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use508
- acute myeloid leukaemia342
- myelosuppression312
- platelet count decreased298
- pneumonia282
- death273
- pyrexia261
- product use issue254
- febrile neutropenia252
- acute myeloid leukaemia recurrent180
- cytopenia167
- infection161
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2016 | 1 |
| 2017 | 4 |
| 2018 | 8 |
| 2019 | 186 |
| 2020 | 359 |
| 2021 | 578 |
| 2022 | 628 |
| 2023 | 619 |
| 2024 | 599 |
| 2025 | 645 |
| 2026 | 452 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Xospata (Gilteritinib Fumarate)
2024 spending
$106M
Beneficiaries
1,048
4,809 claims
Per beneficiary
$101,561
$303.80 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $58,718,494 |
| 2021 | $70,195,773 |
| 2022 | $75,577,732 |
| 2023 | $89,759,419 |
| 2024 | $106,436,061 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML.
Short NJ, Daver N, Dinardo CD, et al. · J Clin Oncol 2024 · Clinical Trial, Phase I, Clinical Trial, Phase II
- Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML.
Perl AE, Martinelli G, Cortes JE, et al. · N Engl J Med 2019 · Clinical Trial, Phase III, Comparative Study
- Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3.
Levis MJ, Hamadani M, Logan B, et al. · J Clin Oncol 2024 · Randomized Controlled Trial, Multicenter Study
- Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML.
Levis MJ, Hamadani M, Logan BR, et al. · Blood 2025 · Clinical Trial, Phase III, Multicenter Study
- Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia.
Daver N, Perl AE, Maly J, et al. · J Clin Oncol 2022 · Clinical Trial, Phase I, Research Support, Non-U.S. Gov't
- Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial.
Perl AE, Larson RA, Podoltsev NA, et al. · Blood 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: Astellas
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.